CAJ | 학술논문

目的观察西黄丸联合介入治疗对中晚期肝癌的临床效果。方法将所有患者随机分为联合组49例和对照组38例，两组均给予经皮肝动脉栓塞化疗(TACE)，联合组在化疗期间给予西黄丸口服治疗。观察两组临床疗效和肿瘤标志物CA19-9的水平变化情况。结果联合组总有效率为57.1%，对照组的总有效率为39.5%，两组差异有显著性(<0.05)；联合组CA19-9水平总有效率为63.3%，对照组的总有效率为36.8%，两组差异有显著性(<0.05)。结论西黄丸联合介入治疗用于肝癌中晚期患者可明显改善患者的临床症状，降低肿瘤标志物水平，恢复患者机体正常功能，有临床推广价值。
목적관찰서황환연합개입치료대중만기간암적림상효과。방법장소유환자수궤분위연합조49례화대조조38례，량조균급여경피간동맥전새화료(TACE)，연합조재화료기간급여서황환구복치료。관찰량조림상료효화종류표지물CA19-9적수평변화정황。결과연합조총유효솔위57.1%，대조조적총유효솔위39.5%，량조차이유현저성(<0.05)；연합조CA19-9수평총유효솔위63.3%，대조조적총유효솔위36.8%，량조차이유현저성(<0.05)。결론서황환연합개입치료용우간암중만기환자가명현개선환자적림상증상，강저종류표지물수평，회복환자궤체정상공능，유림상추엄개치。
Objective To observe the clinical ef ect of Xihuangwan combined with interventional therapy on treatment of advanced hepatocel ular carcinoma.Methods 87cases patients with advanced hepatocel ular carcinoma were randomly divided into Combination group (49 cases)and Control group (38 cases).Both of 2 groups were treated with interventional therapy,and Combination group added Xihuangwan.Observed the clinical ef ect of 2 groups and changes of tumor marker CA19-9 level.Results The total ef ective rate of Combination group (57.1%)was higher than that of control group (37.5%),the dif erence was statistical y significant ( <0.05). The CA19-9 level ef ective rate of Combination group (63.3%)was higher than that of control group(36.8%),the dif erence was statistical y significant ( <0.05).Conclusion Xihuangwan combined with interventional therapy on treatment of advanced hepatocel ular carcinoma can significantly improve the clinical symptoms, reduced tumor marker levels and restore the body's normal function in patients with clinical value.